Gobia Enterprises Invests in Thioredoxin Systems AB

Gobia Enterprises has invested in Thioredoxin Systems AB (TXN Systems), a pharmaceutical company developing a first-in-class antibiotic to combat multidrug-resistant urinary tract infections. With antimicrobial resistance posing a growing global health threat, TXN Systems is pioneering a novel approach to tackling drug-resistant bacterial infections.

The company’s patented antibiotic, EbsArgent™, leverages a unique mechanism of action to enhance treatment efficacy while minimizing resistance development. This innovation has the potential to address a major medical challenge, as urinary tract infections are becoming increasingly difficult to treat with existing antibiotics.

The investment will support the completion of preclinical studies and the initiation of Phase I clinical trials. As part of the funding round, Gobia joins the ownership structure alongside other prominent investors, reinforcing its commitment to groundbreaking life science innovations.

Read more in the full press release on Cision here.